NCT03291938 - IACS-010759 in Advanced Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

November 23, 2020

Study Completion Date

November 23, 2020

Conditions

Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor NegativeHER2/Neu NegativeMetastatic Malignant Solid NeoplasmPancreatic Ductal AdenocarcinomaProgesterone Receptor NegativePrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Recurrent LymphomaRefractory LymphomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Triple-Negative Breast CarcinomaUnresectable Solid Neoplasm

Interventions

DRUG

Oxidative Phosphorylation Inhibitor IACS-010759

Given PO

OTHER

Pharmacodynamic Study

Correlative studies

OTHER

Pharmacokinetic Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER